Day F. Hills, MD
Department of Medicine
Division of Oncology
Seattle Cancer Care Alliance
825 Eastlake Ave E, G4-940
Seattle, WA 98109-1023
Specialty / Expertise
- Head, Neck, Lung, and Thyroid Cancers
Head, Neck, and Lung Cancer
Current Research Projects
Dr. Hills received her MD from Cornell University in New York. She completed her Internal Medicine Residency at New York Presbyterian Hospital/Columbia-Presbyterian Medical Center and her Medical Oncology Fellowship at New York University School of Medicine.
Hochster H, Chen TT, Lu JM, Hills, DF, Sorich J, Escalon,J, Ivy P, Liebes L, Muggia F. Tolerance and activity of oxaliplatin with protracted topotecan infusion in patients with previously treated ovarian cancer. A phase I study. Gynecologic oncology. 2008; 108: 500
Marratta, D and Hills, DF. "Stroke Prevention," Ambulatory Care Syllabus, 4th ed., Division of General Medicine, Miriam Rabkin and Steven Shea, eds., Columbia-Presbyterian Medical Center (2002).
Hills, DF, Apatoff, BR, Trifiletti, RR: Protein tyrosine nitration and anti-nitrotyrosine antibodies in patients with multiple sclerosis. In: Nitric Oxide: Moving toward the clinic. International Business Communications. Scarborough, MA (1996).
Filipov, P, Hills, DF, Trifiletti, RR: CSF nitrite/nitrate in normal neonates and those with IVH. Presentation: 25th Annual Child Neurology Society Meetings. Minneapolis, September, 1996.
Takai, E, Hills, DF, Bandele, AN, Trifiletti, RR; Marked enhancement of protein tyrosine nitration by dystonia-producing toxin 3-nitropropionic acid (3-NP): implications for mechanisms of neurotoxicity. Presentation: 25th Annual Child Neurology Society Meetings. Minneapolis, September, 1996.
Hills, D, Hochster, H et al. "Continuous intravenous infusion (CIVI) topotecan may be safely combined with tipifarnib." ASCO 2006 abstract and poster presentation.
Last updated: May 2011